Cargando…
Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase
BACKGROUND: Florid oral papillomatosis is characterized by its tendency to local recurrence that requires multiple treatments, leading to important functional sequelae. METHODS: We present 74‐year‐old woman with oral florid papillomatosis (OFP) who refused a new surgical treatment, and was treated w...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382048/ https://www.ncbi.nlm.nih.gov/pubmed/35416411 http://dx.doi.org/10.1002/cre2.557 |
_version_ | 1784769214850007040 |
---|---|
author | Ruiz‐Huertas, Pedro Borrego‐Luque, Alicia Toledano‐Valero, Pilar Manzotti, Carolina Rollón‐Mayordomo, Ángel |
author_facet | Ruiz‐Huertas, Pedro Borrego‐Luque, Alicia Toledano‐Valero, Pilar Manzotti, Carolina Rollón‐Mayordomo, Ángel |
author_sort | Ruiz‐Huertas, Pedro |
collection | PubMed |
description | BACKGROUND: Florid oral papillomatosis is characterized by its tendency to local recurrence that requires multiple treatments, leading to important functional sequelae. METHODS: We present 74‐year‐old woman with oral florid papillomatosis (OFP) who refused a new surgical treatment, and was treated with imiquimod 5% in orabase on alternate days for 16 weeks. Treatment was complemented with application of hyaluronic acid gel. RESULTS: There were no side effects to the treatment, nor signs of local recurrence, in the treated area at 2 years of follow‐up. CONCLUSIONS: After reviewing the literature and according to our knowledge, this is the first published case of oral florid papillomatosis treated topically with imiquimod 5% successfully. Topical treatment with imiquimod 5% in orabase may be a valid alternative for patients with recurrent OFP located in the anterior area of the oral cavity who refuse surgical treatment, although we must closely monitor the patient for the possibility of recurrence or malignant degeneration. |
format | Online Article Text |
id | pubmed-9382048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93820482022-08-19 Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase Ruiz‐Huertas, Pedro Borrego‐Luque, Alicia Toledano‐Valero, Pilar Manzotti, Carolina Rollón‐Mayordomo, Ángel Clin Exp Dent Res Short Communication BACKGROUND: Florid oral papillomatosis is characterized by its tendency to local recurrence that requires multiple treatments, leading to important functional sequelae. METHODS: We present 74‐year‐old woman with oral florid papillomatosis (OFP) who refused a new surgical treatment, and was treated with imiquimod 5% in orabase on alternate days for 16 weeks. Treatment was complemented with application of hyaluronic acid gel. RESULTS: There were no side effects to the treatment, nor signs of local recurrence, in the treated area at 2 years of follow‐up. CONCLUSIONS: After reviewing the literature and according to our knowledge, this is the first published case of oral florid papillomatosis treated topically with imiquimod 5% successfully. Topical treatment with imiquimod 5% in orabase may be a valid alternative for patients with recurrent OFP located in the anterior area of the oral cavity who refuse surgical treatment, although we must closely monitor the patient for the possibility of recurrence or malignant degeneration. John Wiley and Sons Inc. 2022-04-13 /pmc/articles/PMC9382048/ /pubmed/35416411 http://dx.doi.org/10.1002/cre2.557 Text en © 2022 The Authors. Clinical and Experimental Dental Research published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Ruiz‐Huertas, Pedro Borrego‐Luque, Alicia Toledano‐Valero, Pilar Manzotti, Carolina Rollón‐Mayordomo, Ángel Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase |
title | Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase |
title_full | Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase |
title_fullStr | Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase |
title_full_unstemmed | Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase |
title_short | Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase |
title_sort | oral florid papillomatosis: topical treatment with 5% imiquimod in orabase |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382048/ https://www.ncbi.nlm.nih.gov/pubmed/35416411 http://dx.doi.org/10.1002/cre2.557 |
work_keys_str_mv | AT ruizhuertaspedro oralfloridpapillomatosistopicaltreatmentwith5imiquimodinorabase AT borregoluquealicia oralfloridpapillomatosistopicaltreatmentwith5imiquimodinorabase AT toledanovaleropilar oralfloridpapillomatosistopicaltreatmentwith5imiquimodinorabase AT manzotticarolina oralfloridpapillomatosistopicaltreatmentwith5imiquimodinorabase AT rollonmayordomoangel oralfloridpapillomatosistopicaltreatmentwith5imiquimodinorabase |